InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
0.8800
-0.0332 (-3.64%)
At close: Mar 18, 2026, 4:00 PM EDT
0.8650
-0.0150 (-1.70%)
After-hours: Mar 18, 2026, 7:58 PM EDT
InflaRx Employees
InflaRx had 74 employees as of December 31, 2024. The number of employees increased by 12 or 18.97% compared to the previous year.
Employees
74
Change (1Y)
12
Growth (1Y)
18.97%
Revenue / Employee
$996
Profits / Employee
-$635,850
Market Cap
59.62M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 74 | 12 | 18.97% |
| Dec 31, 2023 | 62 | 18 | 40.41% |
| Dec 31, 2022 | 44 | -12 | -20.75% |
| Dec 31, 2021 | 56 | 9 | 18.18% |
| Dec 31, 2020 | 47 | 4 | 8.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 142 |
| MindWalk Holdings | 102 |
| Fractyl Health | 101 |
| Mereo BioPharma Group | 36 |
| eXoZymes | 31 |
| Entera Bio | 22 |
| Actuate Therapeutics | 10 |
| Alterity Therapeutics | 9 |
IFRX News
- 13 hours ago - InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 5 days ago - InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewsWire
- 6 days ago - InflaRx to Report Full Year 2025 Results on March 19, 2026 - GlobeNewsWire
- 20 days ago - InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - InflaRx Announces Participation in February Investor Conferences - GlobeNewsWire
- 2 months ago - InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation - GlobeNewsWire
- 2 months ago - InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum - GlobeNewsWire
- 3 months ago - InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904 - GlobeNewsWire